Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo spray shows promise for Hard-to-Treat abdominal cancers

NCT ID NCT06367270

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new method called PIPAC, which sprays chemotherapy directly into the abdomen as a fine mist. It is for people with stomach, pancreas, or colorectal cancer that has spread to the lining of the abdomen. The goal is to see if this approach can control the cancer and improve quality of life. About 60 adults will receive three treatments along with standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years of old; 2. WHO performance of status 0-1; 3. Histologically or cytologically proven PM of a gastric, pancreatic or colorectal carcinoma; 4. Treatment naïve patients as first-line treatment; 5. Progression on or intolerance to first-line systemic chemotherapy as second-line treatment; 6. No symptoms of gastrointestinal obstruction; 7. No contraindications for the planned systemic therapy or laparoscopy; 8. No previous PIPAC/IP/HIPEC; 9. No other concurrent malignancies or any other malignancy within 6 months prior to enrolment; 10. Able to give written informed consent. Exclusion Criteria: 1. A history of allergic reaction to platinum containing compounds or doxorubicin; 2. Pregnant or breastfeeding; 3. Any extra-peritoneal metastases; 4. Renal impairment, defined as GFR less than 40 mL/min; 5. Impaired liver function defined as bilirubin over 1.5 × UNL; 6. Inadequate haematological function * Leucocyte \< 3.00 × 109/L * Absolute neutrophil counts \< 1.50 × 109/L * Platelet \< 100 × 109/L

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peritoneal metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer gastric cancer peritoneal carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peritoneal metastases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Queen Mary Hospital

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.